Elevated DHEA Levels: Evaluation and Management
When DHEA-S (dehydroepiandrosterone sulfate) is elevated, immediately measure the level quantitatively and if >600 µg/dL (16,000 nmol/L), urgently obtain abdominal imaging to rule out an androgen-secreting adrenal adenoma, which often presents with concurrent hypercorticism 1.
Initial Diagnostic Approach
Critical Threshold Assessment
The evaluation algorithm depends entirely on the degree of DHEA-S elevation:
DHEA-S >600 µg/dL: This indicates probable adrenal cortical adenoma and requires urgent abdominal CT or MRI 1. These tumors are frequently associated with Cushing's syndrome and represent a surgical emergency.
DHEA-S moderately elevated (but <600 µg/dL): Proceed with comprehensive androgen panel including total testosterone, free testosterone, SHBG, and androstenedione 2.
Essential Laboratory Workup
Beyond DHEA-S measurement, obtain:
Total and free testosterone: Unbound testosterone is the most frequently elevated androgen in hyperandrogenism (elevated in 82% of hirsute women when combined with DHEA-S assessment) 3
17-hydroxyprogesterone (17OHP): To exclude non-classic 21-hydroxylase deficiency 1
SHBG: Typically reduced with obesity, metabolic syndrome, or family history of diabetes; allows calculation of free testosterone 1
Androstenedione: May be elevated independently of testosterone, particularly when SHBG is reduced 1
Timing and Conditions for Testing
Critical pitfalls to avoid:
- Verify menstrual cycle timing and confirm absence of recent menstruation
- Discontinue thyroid hormones or estrogenic medications (including antiepileptics like valproate) that increase SHBG and confound interpretation 1
- Avoid testing during pregnancy or while on oral contraceptives
Source Localization
Adrenal vs. Ovarian Origin
DHEA-S is primarily of adrenal origin in women 1. However, rare exceptions exist:
Ovarian sex cord-stromal tumors can paradoxically produce elevated DHEA-S despite ovarian tissue lacking sulfotransferase 4. If imaging shows normal adrenals but pelvic mass is present, consider ovarian source.
When testosterone is elevated >2× upper limit of normal with normal DHEA-S, suspect ovarian hyperthecosis or androgen-secreting ovarian tumor 1
Imaging Strategy
- Adrenal imaging: CT or MRI abdomen if DHEA-S >600 µg/dL or if clinical suspicion for tumor
- Pelvic imaging: Ultrasound or MRI if testosterone markedly elevated or palpable mass
- Note: In pediatric cases, even with normal initial MRI, maintain high suspicion for ACTH-secreting pituitary microadenomas if DHEA-S significantly elevated 5
Dynamic Testing
Dexamethasone Suppression Test
Perform when adrenal hyperandrogenism is suspected but tumor excluded:
- Protocol: 0.5 mg dexamethasone at bedtime
- Expected response: Marked decrease in DHEA-S within 2 weeks indicates glucocorticoid-suppressible adrenal hyperandrogenism 2
- Interpretation: Lack of suppression suggests autonomous production (tumor)
ACTH Stimulation
Consider in select cases where adrenal enzyme defects suspected:
- 18% of hirsute women with elevated DHEA-S show exaggerated ACTH-induced rise 3
Clinical Context Assessment
Associated Conditions to Evaluate
Metabolic assessment (given strong correlations):
- Body mass index, waist circumference, waist-to-hip ratio (normal <0.8 in women) 2
- Blood pressure: Significant correlation exists between DHEA-S and both systolic/diastolic BP 6
- Fasting glucose and lipids: Screen for metabolic syndrome
Reproductive history:
- Menstrual pattern (frequency, duration)
- Fertility history, miscarriages
- Age at thelarche, adrenarche, menarche 2
Dermatologic manifestations:
- Hirsutism severity and distribution
- Acne, seborrhea, androgenic alopecia
- Age of onset and progression 2
Management Based on Etiology
Adrenal Adenoma (DHEA-S >600 µg/dL)
Surgical referral for adrenalectomy - this is not a medical management scenario 1
Glucocorticoid-Suppressible Hyperandrogenism
Prednisone 5-7.5 mg or dexamethasone 0.25-0.5 mg daily after supper for 2-3 months 2:
- If androgens normalize, reduce to prednisone 5 mg or dexamethasone 0.25 mg for 2-3 months
- Then halve dose or discontinue
- Monitor androgens every 3-4 months for 1 year
- Expected outcomes: Sustained acne improvement, minor hirsutism improvement (slower growth, softer hair), improved ovulation and fertility 2
Caution: Long-term bone and metabolic effects of minimal-dose glucocorticoids are not well-studied; prefer short-acting prednisone over dexamethasone 2
Combined or Ovarian Hyperandrogenism
When DHEA-S mildly elevated with prominent testosterone elevation:
- Oral contraceptives: Suppress ovarian androgen production
- Antiandrogens (spironolactone, flutamide): Block androgen action
- Insulin-sensitizing agents (metformin, thiazolidinediones): Particularly if metabolic syndrome present 2
- 5α-reductase inhibitors (finasteride): Blocks peripheral androgen conversion 2
Special Populations
Pediatric patients: Maintain high suspicion for ACTH-secreting pituitary microadenomas even with normal initial imaging and near-normal ACTH/cortisol if DHEA-S significantly elevated; close follow-up essential 5
Postmenopausal women: New-onset hyperandrogenism with elevated DHEA-S warrants aggressive tumor workup including both adrenal and ovarian imaging 4